This pharmaceutical company allegedly encouraged physicians to prescribe OxyContin for use every eight hours instead of the 12 hour dose approved by the FDA. Although OxyContin is a Schedule II narcotic with an abuse profile and addictive qualities, Purdue promoted it as a first-choice analgesic for treatment of a wide variety of pain symptoms, minimizing the known risks. This was a multistate case. Purdue Pharma paid $19.5 million to 26 states, including Tennessee and the District of Columbia. Tennessee received $719,500 from the settlement.
This list includes only significant filings and is not intended to be a complete record of the matter.